The risk of chronic kidney disease (CKD) may be increased in patients living with HIV receiving tenofovir (TDF) with a ritonavir-boosted protease inhibitor compared to those who receive TDF with a non-nucleosidic reverse transcriptase inhibitor (NNRTI)
The researchers found that among 495 patients with undetectable CMV DNA at randomization, fewer patients in the letermovir group had clinically significant CMV infection or were classified as having a primary end point event by week 24 after transplantation, compared with the placebo group.
A list of contraindications and drug interactions for HIV medications.
Diagnose, treat, and prevent community acquired pneumonia using key recommendations from the IDSA/ATS CAP guidelines.
Oral and topical vaginal infection treatment options for vulvovaginal candidiasis and bacterial vaginosis.
All PWLH should receive brief standardized screening for chronic pain. A biopsychosocial approach should be used; and appropriate monitoring should take place.
Criteria for recommending postexposure prophylaxis (PEP) to HIV following occupational exposure
Criteria for recommending postexposure prophylaxis (PEP) to HIV following sexual assault
Regardless of the cytology result, 5-year ≥CIN3 risks for an HPV-negative co-test nearly matched the performance of a negative co-test for each successive round of screening (0.114, 0.061, and 0041%, respectively).
Twelve percent of the 554 children who the treating clinicians thought were unlikely to have Lyme disease had Lyme disease, and 31% of those who the treating clinicians thought were very likely to have Lyme disease did not have Lyme disease.
Juluca combines dolutegravir, an HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, a non-nucleoside reverse transcriptase inhibitor.
The investigators determined that empiric treatment of 4 patients with acute respiratory illness who were considered high-risk was needed to treat 1 with positive influenza laboratory tests.
The Food and Drug Administration (FDA) has approved updated labeling for several hepatitis C virus (HCV) infection treatments.
Of 100 participants, 32% had EPI (faecal elastase-1 <200 μg/g) and 20% severe EPI (faecal elastase-1 <100 μg/g).
The primary endpoint of symptom resolution at day 3 was met by 54% (72/133) in the diclofenac group vs. 80% (96/120) in the norfloxacin group (risk difference 27%, 95% CI 15% to 38%, P=0.98 for non-inferiority, P<0.001 for superiority).
Prevymis, a non-nucleoside CMV inhibitor (3,4 dihydro-quinazoline), inhibits viral replication through targeting the viral terminase complex.
Data were included for 262 patients with a history of WNV enrolled in a longitudinal cohort from 2002 to 2012; 117 patients underwent neurologic and neurocognitive evaluations.
The authors write, "the advent of direct acting antiviral (DAA) agent therapies has resulted in significant improvements in treatment rates for those with co-infection."